Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Autor: Conteduca, V., Wetterskog, D., Sharabiani, M.T.A., Grande, E., Fernandez-Perez, M.P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vazquez-Estevez, S., González del Alba, A., Mellado, B., Fernandez-Calvo, O., Méndez-Vidal, M.J., Climent, M.A., Duran, I., Gallardo, E., Rodriguez, A., Santander, C., Sáez, M.I., Puente, J., Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., De Giorgi, U., Gonzalez-Billalabeitia, E. ^*, Attard, G. ^*

Publikováno v: In Annals of Oncology July 2017 28(7):1508-1516

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Autor: Vincenza Conteduca, Jayaram, A., Romero-Laorden, N., Wetterskog, D., Salvi, S., Gurioli, G., Scarpi, E., Castro, E., Marin-Aguilera, M., Lolli, C., Schepisi, G., Maugeri, A., Wingate, A., Farolfi, A., Casadio, V., Medina, A., Puente, J., Vidal, Mjm, Morales-Barrera, R., Villa-Guzmán, Jc, Hernando, S., Rodriguez-Vida, A., González-Del-Alba, A., Mellado, B., Gonzalez-Billalabeitia, E., Olmos, D., Attard, G., Giorgi, U.

Publikováno v: European Urology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Università degli studi di Foggia-IRIS

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5a3b2d792bd066c01c1b2f901c9f01ab
http://europepmc.org/articles/PMC6377278

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.

Autor: Salvi, S¹, Casadio, V¹, Conteduca, V², Burgio, S L², Menna, C², Bianchi, E², Rossi, L², Carretta, E³, Masini, C⁴, Amadori, D², Calistri, D¹, Attard, G⁵, De Giorgi, U²

Publikováno v: British Journal of Cancer. 5/12/2015, Vol. 112 Issue 10, p1717-1724. 8p. 2 Charts, 3 Graphs.

Apollonio Rodio 'interprete' di Omero: il 'rebus' geografico delle Πλαγταί

Autor: Casadio, V

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3667::0ec6e14f752805717e462fd566daab6e
http://hdl.handle.net/2108/206846

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Autor: Conteduca, V, Wetterskog, D, Sharabiani, M. T. A, Grande, Elisabetta, Fernandez Perez, M. P, Jayaram, A, Salvi, S, Castellano, D, Romanel, Alessandro, Lolli, C, Casadio, V, Gurioli, G, Amadori, D, Font, A, Vazquez Estevez, S, González Del Alba, A, Mellado, B, Fernandez Calvo, O, Méndez Vidal, M. J, Climent, M. A, Duran, I, Gallardo, E, Rodriguez, A, Santander, C, Sáez, M. I, Puente, J, Gasi Tandefelt, D, Wingate, A, Dearnaley, D, Demichelis, Francesca, De Giorgi, U, Gonzalez Billalabeitia, E, Attard, G.

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Background There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex drople

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::cf900af5576862f3c12c6db4cb765b76
http://hdl.handle.net/10044/1/71596